scanX
Shilpa Medicare
add_icon

Shilpa Medicare

341.50
-8.65
(-2.47%)
Market Cap
₹6,679.12 Cr
PE Ratio
50.78
Volume
1,81,899.00
Day High - Low
₹349.95 - ₹340.00
52W High-Low
₹1,000.00 - ₹277.50
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
6,679.12 Cr
EPS
8.04
PB Ratio
2.86
Book Value
124.61
EBITDA
340.20
Dividend Yield
0.14 %
Industry
Healthcare
Sector
Pharmaceuticals
ROE Growth %
-
Debt to Equity
0.36
Forecast For
Actual

Company News

View All News
Caret
neutral
Shilpa Medicare Receives FDA Form 483 with Eight Observations After Facility Inspection6 days ago
The USFDA completed a 10-day inspection of Shilpa Medicare's Unit IV facility in Jadcherla, Telangana, and issued a Form 483 containing eight observations. The company noted that none of the observations are repeat in nature, indicating they are new regulatory findings from this inspection.
neutral
USFDA Issues Form 483 With Eight Observations After Inspecting Shilpa Medicare's Jadcherla Unit IV8 days ago
The USFDA completed a 10-day inspection at Shilpa Medicare's Jadcherla Unit IV facility and issued a Form 483 citing eight new regulatory observations. This regulatory action affects Shilpa Medicare's manufacturing operations and indicates areas requiring corrective measures to meet FDA compliance standards.
positive
Shilpa Medicare Reports Record Q2 FY26 Results with Highest Quarterly EBITDA of INR 110 CroresNov 19, 2025
Shilpa Medicare achieved highest quarterly revenues of INR 372 crores (7% YoY growth) and crossed INR 100 crores EBITDA milestone for first time, with 30% EBITDA margin and 21% growth. The company launched its first NCE product NorUDCA in India and expects commercial supplies from multiple pipeline products including NCE programs, Semaglutide, and biosimilars to drive future growth across API, formulations and biologics segments.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,831.60
#1 4,39,462.19
40.68
#1 54,729.00
9.71
#1 10,980
2.89
79.43
Divis Laboratories
6,477.00
1,71,944.00
69.05
9,712.00
18.67
2,191
35.10
49.62
Torrent Pharmaceuticals
3,720.60
1,25,922.01
58.80
11,539.40
6.99
1,911
30.46
53.11
Cipla
1,531.30
1,23,691.38
22.73
28,409.50
7.12
5,291
3.71
50.63
Dr Reddys Laboratories
1,258.80
1,05,061.18
#1 18.15
33,741.20
16.73
5,725
-0.38
57.24
Lupin
2,082.20
95,105.43
21.34
22,909.50
13.74
3,306
#1 72.75
65.07
Zydus Life Science
942.50
94,837.55
18.56
23,511.00
18.55
4,615
34.60
44.36
Mankind Pharma
2,251.00
92,911.94
52.05
12,744.20
#1 20.90
2,007
-21.05
38.76
Aurobindo Pharma
1,226.70
71,246.94
20.70
32,345.60
9.43
3,484
3.81
63.81
Alkem Laboratories
5,685.00
67,972.70
28.29
13,458.30
3.70
2,216
10.98
53.82
Growth Rate
Revenue Growth
12.92 %
Net Income Growth
144.69 %
Cash Flow Change
-3.29 %
ROE
85.96 %
ROCE
23.15 %
EBITDA Margin (Avg.)
19.23 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
168
151
177
202
203
168
219
186
231
174
209
191
241
203
192
177
203
163
296
241
229
289
288
200
215
239
306
278
346
269
267
266
266
262
315
289
300
302
349
321
341
328
372
Expenses
129
120
137
158
146
139
161
151
171
133
155
159
189
149
128
153
163
132
223
163
175
158
210
171
182
206
243
228
268
241
253
231
227
214
255
222
222
223
258
239
282
231
262
EBITDA
39
31
40
44
58
30
58
35
60
40
54
31
53
54
64
24
41
31
73
78
54
131
78
29
33
33
62
50
78
28
14
34
39
48
60
67
79
80
91
82
59
97
110
Operating Profit %
23 %
19 %
21 %
21 %
26 %
16 %
23 %
17 %
23 %
20 %
24 %
14 %
20 %
25 %
21 %
12 %
19 %
18 %
23 %
31 %
21 %
29 %
25 %
11 %
12 %
13 %
18 %
16 %
21 %
8 %
4 %
12 %
14 %
18 %
19 %
23 %
24 %
24 %
25 %
25 %
15 %
28 %
29 %
Depreciation
5
5
6
6
6
7
7
8
8
9
8
9
11
10
10
11
11
11
11
11
12
12
13
14
15
18
19
21
22
22
23
24
26
27
28
27
27
27
28
29
29
29
30
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
4
4
5
9
10
12
10
9
10
14
18
18
18
23
26
24
24
26
12
15
19
16
Profit Before Tax
32
25
34
37
50
22
50
27
51
31
46
22
41
43
53
11
29
19
62
65
42
115
61
11
8
5
32
19
46
-4
-22
-8
-4
3
9
14
28
29
37
42
15
50
64
Tax
10
7
12
10
12
8
12
10
14
9
12
5
10
10
11
-1
6
4
11
11
8
29
16
3
1
4
12
10
17
-6
-4
-1
4
2
8
10
3
15
19
10
1
3
20
Net Profit
22
18
22
27
38
14
38
17
37
22
34
16
31
33
42
12
23
15
51
55
34
86
45
8
8
2
20
10
30
2
-19
-7
-8
1
2
5
25
14
18
32
15
47
44
EPS in ₹
5.86
4.70
6.05
3.60
4.27
1.92
4.97
2.03
4.33
2.77
4.21
2.29
3.79
4.28
5.22
1.46
2.93
1.93
6.23
6.75
4.24
10.59
5.57
0.94
0.96
0.19
2.45
1.13
3.40
0.10
-2.15
-0.76
-0.93
0.14
0.19
0.53
2.82
1.46
1.83
3.25
1.48
4.79
5.50
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Fixed Assets
316
393
492
534
558
650
1,111
1,342
1,368
1,385
1,418
Current Assets
328
354
730
672
545
624
903
887
770
877
986
Capital Work in Progress
222
92
141
210
429
666
541
506
655
719
822
Investments
65
94
253
140
2
11
21
34
43
40
35
Other Assets
302
352
587
615
621
662
959
993
838
950
1,037
Total Liabilities
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Current Liabilities
189
222
237
266
253
411
604
612
784
693
674
Non Current Liabilities
154
67
251
154
167
257
561
453
345
600
273
Total Equity
561
642
984
1,080
1,190
1,322
1,468
1,811
1,774
1,800
2,364
Reserve & Surplus
539
632
979
1,077
1,189
1,321
1,471
1,814
1,775
1,800
2,363
Share Capital
8
8
8
8
8
8
8
9
9
9
10
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
9
3
93
-26
-40
10
79
-98
-7
13
-3
Investing Activities
-196
-106
-257
-10
-196
-290
-404
-286
-232
-171
-198
Operating Activities
69
129
38
45
147
124
47
105
180
137
132
Financing Activities
136
-20
313
-61
10
176
436
83
46
47
63
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Apr 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
53.25 %
53.25 %
53.25 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
44.39 %
44.39 %
44.33 %
44.23 %
44.23 %
44.23 %
44.23 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.60 %
8.52 %
0.00 %
0.00 %
9.08 %
9.58 %
9.90 %
10.97 %
11.20 %
10.92 %
DIIs
2.95 %
2.05 %
2.29 %
2.15 %
2.12 %
1.01 %
1.01 %
1.01 %
0.61 %
0.54 %
0.00 %
0.41 %
0.06 %
1.59 %
6.13 %
7.61 %
8.18 %
8.27 %
7.55 %
7.46 %
7.67 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.80 %
17.89 %
19.49 %
18.23 %
18.57 %
20.12 %
20.51 %
18.95 %
21.85 %
24.05 %
26.82 %
25.40 %
25.45 %
27.64 %
24.54 %
24.69 %
23.94 %
24.40 %
24.43 %
23.21 %
23.34 %
Others
27.01 %
26.81 %
24.97 %
29.61 %
29.31 %
28.87 %
28.47 %
30.03 %
27.52 %
25.40 %
23.17 %
15.59 %
15.96 %
20.75 %
24.94 %
14.23 %
13.96 %
13.21 %
12.83 %
13.90 %
13.84 %
No of Share Holders
51,277
53,220
46,540
40,592
39,565
39,724
39,097
41,579
46,143
46,869
50,434
44,094
43,630
44,793
44,809
41,072
42,784
49,034
50,108
48,636
52,065

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.6 0.6 0.7 1 1.1 1.1 1.1 0.00 0.00 1
Dividend Yield (%) 0.19 0.26 0.41 0.82 0.66 0.55 0.96 0.00 0.00 0.29

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Sept 2021 DIVIDEND Dividend
₹ 1.10 /share
 20 Sept 2021 257.93 277.10
20 Sept 2022 DIVIDEND Dividend
₹ 1.10 /share
 19 Sept 2022 210.73 187.95
17 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 17 Sept 2024 353.38 447.35
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2024 421.15 437.78
10 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 10 Feb 2025 347.75 365.43
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 26 May 2025 353.98 390.75
13 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Aug 2025 850.40 870.20
17 Sept 2025 DIVIDEND Dividend
₹ 1.00 /share
 17 Sept 2025 390.75 413.13
23 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 23 Sept 2025 870.20 408.63
03 Oct 2025 BONUS Bonus
1:1
 03 Oct 2025 410.33 390.50
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2025 358.20 399.65

Announcements

USFDA Inspection Of Shilpa Medicare Ltd. Unit IV Jadcherla Telangana8 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 17, 2025
Announcement Under Regulation 30 Of The SEBI(LODR) Regulations.Nov 17, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesNov 13, 2025
Outcome Of The Board Meeting Of The Company Held On 13 November 2025Nov 13, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On 13 November 2025Nov 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotNov 10, 2025
Announcement Under Regulation 30 Of The SEBI(LODR) Regulations 2015Nov 10, 2025
Announcement Under Regulation 30 Of The SEBI(LODR) Regulations 2015Nov 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Board Meeting Intimation for Consider And Approve Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended 30 September 2025Nov 05, 2025
Announcement Under Regulation 30 & 30(A) Of The SEBI (LODR) Regulations 2015Oct 27, 2025
Intimation Under Regulation 30 Read With Regulation 30A And Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Oct 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 09, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotOct 07, 2025
Announcement under Regulation 30 (LODR)-AllotmentOct 06, 2025
NSE - In Principle Approval For Bonus IssueSep 29, 2025
Promoter Reclassificion - NOC From BSESep 27, 2025
In-Principle Approval For Bonus IssueSep 26, 2025
Promoter Reclassificaiton - NOC From NSESep 26, 2025
Closure of Trading WindowSep 26, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 24, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 23, 2025
Announcement under Regulation 30 (LODR)-CessationSep 23, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 23, 2025
Initial Authorization For Rivaroxaban Orodispersible Films From EuropeSep 22, 2025
Reg. 34 (1) Annual Report.Sep 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Dispatch Of Letters To Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent/ Depository ParticipantsAug 28, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 ("SEBI Listing Regulations")Aug 28, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 ("SEBI Listing Regulations")Aug 28, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesAug 26, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Annual ReportAug 26, 2025
AGM NoticeAug 26, 2025
Intimation Of Revised Record Date For Bonus IssueAug 22, 2025
Intimation For Participation In Investor ConferenceAug 18, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Intimation Of Submission Of Application For Reclassification Of Promoter/ Promoter Group From Promoter Group Category To "Public Category Pursuant To Regulation 31A (8) (C) Of SEBI (LODR) Regulations 2015Aug 13, 2025
Intimation Under 31A Of The SEBI (LODR) Regulations 2015 For Reclassification From Promoter/Promoter Group To Public CategoryAug 13, 2025
Corporate Action-Board recommends Bonus IssueAug 13, 2025
Record Date Of Bonus IssueAug 13, 2025
Record Date For The Purpose Of DividendAug 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Results - Financial ResultsAug 13, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Small Cap Fund Direct-Growth
0.45%
1112941
-0.08%
-0.19%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.49%
1032968
-0.05%
-0.12%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
1.06%
963149
-0.11%
-0.27%
HDFC Pharma And Healthcare Fund Direct - Growth
0.89%
494000
0.89%
0.89%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.28%
322701
0.15%
0.18%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
1.78%
313482
0.75%
0.64%
Aditya Birla Sun Life Manufacturing Equity Fund Direct-Growth
0.69%
219227
0.69%
0.69%
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth
0.49%
189734
-0.05%
-0.14%
ICICI Prudential Exports and Services Fund Direct-Growth
0.37%
150000
0.37%
0.37%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.25%
146041
-0.04%
-0.09%
Bandhan Innovation Fund Direct-Growth
0.44%
119273
-0.06%
-0.46%
WhiteOak Capital Special Opportunities Fund Direct - Growth
0.57%
102771
-0.08%
-0.20%
WhiteOak Capital Multi Cap Fund Direct - Growth
0.20%
73752
-0.03%
-0.08%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.61%
41296
-0.10%
-0.22%
Aditya Birla Sun Life Retirement Fund - The 30s Plan Direct-Growth
0.65%
39550
-0.07%
-0.17%
WhiteOak Capital Balanced Advantage Fund Direct - Growth
0.11%
30475
-0.01%
-0.04%
ITI Pharma and Healthcare Fund Direct - Growth
0.75%
24784
-0.07%
-0.17%
WhiteOak Capital ELSS Tax Saver Fund Direct - Growth
0.28%
17272
-0.03%
-0.08%
WhiteOak Capital Multi Asset Allocation Fund Direct - Growth
0.02%
10016
0.00%
-0.01%
WhiteOak Capital Balanced Hybrid Fund Direct - Growth
0.14%
4939
-0.02%
-0.05%
Groww Nifty Total Market Index Fund Direct - Growth
0.02%
894
0.00%
-0.01%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.28%
733
-0.03%
-0.07%
Angel One Nifty Total Market Index Fund Direct - Growth
0.02%
137
0.00%
-0.01%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.02%
125
0.00%
-0.01%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.02%
103
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
39.09
ATR(14)
Less Volatile
14.94
STOCH(9,6)
Oversold
12.41
STOCH RSI(14)
Oversold
3.10
MACD(12,26)
Bearish
-2.34
ADX(14)
Weak Trend
19.79
UO(9)
Bearish
41.13
ROC(12)
Downtrend And Accelerating
-10.99
WillR(14)
Oversold
-87.16
Bearish
4
Neutral
3
Bullish
2
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104